Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer

Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer

(2009) Miguel Martín et al.   BREAST CANCER RESEARCH AND TREATMENT

Reduction of CD44+/CD24− breast cancer cells by conventional cytotoxic chemotherapy

(2009) Sebastian Aulmann et al.   HUMAN PATHOLOGY

Anthracyclines and Early Breast Cancer: The End of an Era?

(2009) Luca Gianni et al.   JOURNAL OF CLINICAL ONCOLOGY

Topoisomerase IIα Amplification Does Not Predict Benefit From Dose-Intense Cyclophosphamide, Doxorubicin, and Fluorouracil Therapy inHER2-Amplified Early Breast Cancer: Results of CALGB 8541/150013

(2009) Lyndsay N. Harris et al.   JOURNAL OF CLINICAL ONCOLOGY

Topoisomerase IIα Amplification and Anthracycline-Based Chemotherapy: The Jury Is Still Out

(2009) Francisco J. Esteva et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcome of Patients With Early-Stage Breast Cancer Treated With Doxorubicin-Based Adjuvant Chemotherapy As a Function ofHER2andTOP2AStatus

(2009) Raymond Tubbs et al.   JOURNAL OF CLINICAL ONCOLOGY

AreHER2andTOP2AUseful As Prognostic or Predictive Biomarkers for Anthracycline-Based Adjuvant Chemotherapy for Breast Cancer?

(2009) Kathleen I. Pritchard   JOURNAL OF CLINICAL ONCOLOGY

Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial

(2009) Judith Hugh et al.   JOURNAL OF CLINICAL ONCOLOGY

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735

(2009) Stephen Jones et al.   JOURNAL OF CLINICAL ONCOLOGY

Ki67 Expression and Docetaxel Efficacy in Patients With Estrogen Receptor–Positive Breast Cancer

(2009) Frédérique Penault-Llorca et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cyclophosphamide, Methotrexate, and Fluorouracil, As Adjuvant or Primary Systemic Therapy: European Cooperative Trial in Operable Breast Cancer

(2009) Luca Gianni et al.   JOURNAL OF CLINICAL ONCOLOGY

Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes

(2009) Joel S. Parker et al.   JOURNAL OF CLINICAL ONCOLOGY

Alterations in the TOP2A and HER2 Genes: Association With Adjuvant Anthracycline Sensitivity in Human Breast Cancers

(2009) D. J. Slamon et al.   JNCI-Journal of the National Cancer Institute

Topoisomerase II Alpha and Responsiveness of Breast Cancer to Adjuvant Chemotherapy

(2009) F. P. O'Malley et al.   JNCI-Journal of the National Cancer Institute

Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

(2009) Maggie C. U. Cheang et al.   JNCI-Journal of the National Cancer Institute

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

(2009) Paul Ellis et al.   LANCET

Class III  -Tubulin Isotype Predicts Response in Advanced Breast Cancer Patients Randomly Treated Either with Single-Agent Doxorubicin or Docetaxel

(2008) C. M. Galmarini et al.   CLINICAL CANCER RESEARCH

Insulin-Like Growth Factor-I Activates Gene Transcription Programs Strongly Associated With Poor Breast Cancer Prognosis

(2008) Chad J. Creighton et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02 98 Randomized Trial

(2008) P. Francis et al.   JNCI-Journal of the National Cancer Institute

Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

(2008) M. Martin et al.   JNCI-Journal of the National Cancer Institute

HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials

(2007) Alessandra Gennari et al.   JNCI-Journal of the National Cancer Institute